Dr. Dajun Yang Ranks Top 3 on Medicine Maker Power List 2026

Industry peers and expert judges selected Dr. Dajun Yang for The Medicine Maker Power List 2026. The prestigious publication ranked the Chairman and CEO of Ascentage Pharma third in the Small Molecules category. The annual list honors sixty global leaders who drive biopharmaceutical innovation, manufacturing, and global patient access. Under his guidance, the organization actively advances targeted cancer therapies that address major gaps in modern healthcare. He brings over thirty years of deep experience in apoptosis pathways and precision medicine.

Global experts recognize his long-standing work in clinical research and business growth. Organizations that focus on small molecule cancer therapies can transform options for complex hematologic cancers. His vision helped build a pipeline of treatments with first-in-class potential. For example, his team secured regulatory approval in China for olverembatinib. This drug represents a key third-generation inhibitor for specific leukemia cases.

Additionally, his leadership brought lisaftoclax to market for chronic lymphocytic leukemia patients. This breakthrough marked only the second approved Bcl-2 inhibitor globally since 2016. The team now conducts several international registrational trials across diverse indications.

Advancing Global Clinical Trials

Dr. Yang directs multiple Phase III studies across North America, Europe, and Asia. Four of these international trials received clear regulatory clearance from both the FDA and EMA. Therefore, the company rapidly expands its global footprint and clinical research presence.

Furthermore, lisaftoclax remains the only Bcl-2 inhibitor in a global Phase III study for high-risk MDS. The company continuously explores novel therapeutic approaches like targeted protein degradation. These clinical milestones demonstrate steady scientific progress and operational excellence.

As a result, the enterprise achieved successful dual primary listings on both Hong Kong and Nasdaq exchanges. This financial foundation allows researchers to accelerate novel drug pipelines efficiently. Industry partners consistently value this sustained commitment to rigorous scientific discovery.

Transforming Patient Care Globally

The organization recently completed a major business deal for small molecule development in China. Consequently, this commercial momentum strengthens their ability to deliver new medicines to patients faster. The leadership team remains focused on expanding trial sites worldwide.

Moreover, ongoing research targets both blood cancers and solid tumor indications simultaneously. The clinical teams refine dosing strategies to optimize patient outcomes and safety profiles. These systematic efforts position the firm as a global leader in oncology innovation.

Dr. Yang emphasizes that teamwork and dedicated science drive every single breakthrough. His team continues to tackle difficult medical challenges with advanced research platforms. Their work gives new hope to individuals facing limited treatment options today.

Discover Health Tech Insiders for the latest advancements in medical technology and trusted strategic insights shaping the future of tech-driven healthcare transformation.